

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

Claims 1-77 (Canceled)

78. (Currently Amended) A lymph node homing peptide ~~selected from the group consisting of~~ AGCSVTVCG (SEQ ID NO:315), GSCSMFPCS (SEQ ID NO:317), SECAYRACS (SEQ ID NO: 319), WSCARPLCG (SEQ ID NO: 320), GLCQIDECR (SEQ ID NO: 329), DRCLDIWCL (SEQ ID NO: 331), PLCMATRCA (SEQ ID NO: 333), RDCSHRSCE (SEQ ID NO:334), NPCLRAACI (SEQ ID NO: 335), which is PTCAYGWCA (SEQ ID NO: 336), LECVANLCT (SEQ ID NO: 337), RKC GEEVCT (SEQ ID NO: 338), EPCTWNACL (SEQ ID NO: 339) ~~and QQCQDPYCL (SEQ ID NO:344).~~

79. (Currently Amended) A conjugate, comprising the peptide which is PTCAYGWCA (SEQ ID NO: 336) ~~of claim 78~~ linked to a moiety.

80. (Previously Presented) The conjugate of claim 79, wherein said moiety is selected from the group consisting of a therapeutic agent, a detectable agent and a tag.

81. (Currently Amended) A method of identifying lymph node, comprising the steps of:  
a) contacting a tissue or organ with a peptide which is PTCAYGWCA (SEQ ID NO: 336) ~~of claim 78~~; and

b) detecting binding of said peptide to said organ or tissue, thereby identifying the organ or tissue as lymph node.

82. (Previously Presented) A method of identifying a target molecule expressed by lymph node, comprising the method of claim 81, further comprising the steps of:

c) obtaining a sample of said lymph node; and

d) identifying the target molecule, which is bound by said peptide.

83. (Currently Amended) A method of treating a lymph node pathology in a subject, comprising administering a peptide which is PTCAYGWCA (SEQ ID NO: 336) linked to a therapeutic agent of claim 78 to the subject, wherein said peptide selectively homes to lymph node, thereby treating the lymph node pathology.